MA-IMMERSIVE-LABS
14.6.2021 10:02:14 CEST | Business Wire | Press release
Immersive Labs, the company empowering organizations to measure and improve cybersecurity skills across technical and non-technical teams, today announced it has closed $75m in Series C funding led by new investors Insight Partners alongside Menlo Ventures , Citi Ventures and existing investor Goldman Sachs Asset Management .
The investment will accelerate delivery of a progressive new Cyber Workforce Optimization platform. With cyber risk no longer confined to technical specialists, expert skills are now required across the entire organization. From crisis management with executives to secure software development amongst engineers and ensuring compliance in legal teams, the platform will use data insights to understand where skills are required and inject role-specific training. It will also enable board-level metrics and benchmarking.
Immersive Labs, which has now received $123m in venture funding, currently counts organizations such as HSBC, Vodafone and the NHS as customers. Growing at over 100% year-on-year, it has recently been named in numerous industry and business awards as an innovation leader.
James Hadley, CEO and Founder of Immersive Labs, said, “With cyber risk becoming a problem for a growing number of business functions, cybersecurity knowledge and skills should no longer be the preserve of a few technical people hidden away in a back office. Everyone from the teams who build software to the CEO now needs to play their part in addressing a pervasive company issue. This requires unlocking and evidencing skills in a much broader group of people.
“The first step to achieving this lies in understanding where capabilities are lacking which, until now, has been impossible. This investment will allow us to add new analytical capabilities and content to provide a more detailed picture of skills across the growing breadth and depth of cyber exposure facing organizations, helping them measure and manage risk better.”
“With significant global customer and revenue growth over the last few years, Immersive Labs has established a strong position in the fast-developing cyber skills space,” said Ryan Hinkle, Managing Director at Insight Partners. “With influential leadership, an innovative product in a growing market and strong user engagement, the company is in a position to continue to lead the cyber readiness market.” As part of the transaction, Hinkle will be joining the company’s Board of Directors.
As well as building out the platform, Immersive Labs will use the funding to expand its international presence, tripling global headcount to 600 over the next two years and establishing operations in new regions throughout APAC and Europe.
“The labor crisis in cybersecurity is a hard problem to solve. To protect against ever-evolving threats, the cyber workforce must constantly expand and evolve. Immersive Labs helps large organizations confront this head-on by combining smart data analysis with targeted training,” said Venky Ganesan, Partner at Menlo Ventures. “As a veteran cybersecurity investor, I find the opportunity for Immersive Labs to solve a massive problem with a horizontal solution exciting. The cybersecurity threat will only increase, making Immersive Labs futureproof as they seek to help large enterprises educate and arm themselves against ever-evolving threats.”
Arvind Purushotham, Managing Director and Global Head of Citi Ventures, said, “We believe strongly in the value of using people more strategically to help large organizations mitigate ever-growing cyber risk. Traditionally, this has been difficult; without effective data, it’s hard to know where to apply skills development and how to measure its success. This is why Immersive Labs’ vision is so compelling – it creates visibility into and optimizes one of the most valuable assets in cyber defense, the human defenders.”
James Hayward, Managing Director in the Growth Equity team at Goldman Sachs Asset Management, said: “Immersive Labs has proven itself to be a valuable partner for businesses looking to improve their resilience to cyber risks. Their growth and development in the three years since we initially invested has been impressive and we believe they have built a strong foundation for further growth.”
Since founding in 2017, Immersive Labs has grown to over 200 people, with joint operations HQs in Bristol and Boston. For more information on the company visit immersivelabs.com
About Immersive Labs
Immersive Labs is empowering organizations to equip, exercise, and evidence human cyber capabilities. We provide metrics that give security leaders insight into human cyber skills and readiness levels across their organization and improve these through dynamic labs and crisis scenarios which track the threat landscape. Immersive Labs is backed by Goldman Sachs Asset Management, Summit Partners, Insight Partners, Citi Ventures, and Menlo Ventures. Our customers include some of the largest companies in financial services, healthcare, and government, amongst others. For more information on Immersive Labs’ offering, please visit www.immersivelabs.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005076/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
